EFFECTOR THERAPEUTICS
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch EFTR and buy or sell other stocks, ETFs, and their options commission-free!About EFTR
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). Its STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2).
CEOStephen T. Worland
CEOStephen T. Worland
Employees15
Employees15
HeadquartersSolana Beach, California
HeadquartersSolana Beach, California
Founded2012
Founded2012
Employees15
Employees15
EFTR Key Statistics
Market cap12.92K
Market cap12.92K
Price-Earnings ratio-12.57
Price-Earnings ratio-12.57
Dividend yield—
Dividend yield—
Average volume2.96M
Average volume2.96M
High today$0.0002
High today$0.0002
Low today$0.0002
Low today$0.0002
Open price$0.0002
Open price$0.0002
Volume188.00
Volume188.00
52 Week high$1.48
52 Week high$1.48
52 Week low$0.0002
52 Week low$0.0002
Stock Snapshot
With a market cap of 12.92K, EFFECTOR THERAPEUTICS(EFTR) trades at $0.00. The stock has a price-to-earnings ratio of -12.57.
On 2025-12-13, EFFECTOR THERAPEUTICS(EFTR) stock moved within a range of $0.00 to $0.00. With shares now at $0.00, the stock is trading 0.0% above its intraday low and 0.0% below the session's peak.
Trading volume for EFFECTOR THERAPEUTICS(EFTR) stock has reached 188, versus its average volume of 2.96M.
The stock's 52-week range extends from a low of $0.00 to a high of $1.48.
The stock's 52-week range extends from a low of $0.00 to a high of $1.48.
People also own
Based on the portfolios of people who own EFTR. This list is generated using Robinhood data, and it’s not a recommendation.